Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Trading 10-09 10:02:16 EDT

85.04

+1.63

+1.95%

High85.06	Low83.25	Vol104.32M
Open83.41	D1 Closing83.41	Amplitude2.17%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O2.50B	T/O Rate--	Tradable Shares0.00
P/B7.91203	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":85.04324,"timestamp":1791554536343,"preClose":83.41436,"halted":0,"volume":104322484,"delay":0,"changeRate":0.019528,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":1.628883,"latestTime":"10-09 10:02:16 EDT","open":83.41436,"high":85.055115,"low":83.24833,"amount":2495548565.992749,"amplitude":0.02166,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.91203,"peRate":-120.259308,"turnoverRate":0.002957,"increases":396,"decrements":100,"flats":18,"marketCap":2161944174557.1875,"floatMarketCap":1984693852437.0625},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"1147549789","title":"Iambic Therapeutics Sets IPO Price Range at $15-$17 per Share to Raise $150 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1147549789","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147549789?lang=en_us&edition=fundamental","pubTime":"2026-10-09 14:58","pubTimestamp":1791529094,"startTime":"0","endTime":"0","summary":"Iambic Therapeutics Inc (IAM.US), a clinical-stage biotechnology company developing small molecule cancer therapies through its proprietary artificial intelligence (AI) platform, announced the terms...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IAM","BK4139","WDNA","UUP","IPOS","BK4007","UDN","BK4539","LENZ","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172839647","title":"Ascentage Pharma: A Dancer on the High Wire","url":"https://stock-news.laohu8.com/highlight/detail?id=1172839647","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172839647?lang=en_us&edition=fundamental","pubTime":"2026-10-09 14:21","pubTimestamp":1791526895,"startTime":"0","endTime":"0","summary":"Based on publicly available information. This is for informational exchange only and does not constitute any investment advice.Innovative drug development is a business of trading time for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","BK4139","BK1161","AAPG","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674683523","title":"Immutep Moves to Restore ASX Audit Committee Compliance After Director Exit","url":"https://stock-news.laohu8.com/highlight/detail?id=2674683523","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674683523?lang=en_us&edition=fundamental","pubTime":"2026-10-09 14:14","pubTimestamp":1791526479,"startTime":"0","endTime":"0","summary":"An update from Immutep Ltd ( ($AU:IMM) ) is now available. Immutep has disclosed that its Audit and Risk Committee no longer complies with ASX List...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immutep-moves-to-restore-asx-audit-committee-compliance-after-director-exit?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immutep-moves-to-restore-asx-audit-committee-compliance-after-director-exit?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674833650","title":"Argenx Se : Jefferies Cuts Target Price to $1,200 from $1,235","url":"https://stock-news.laohu8.com/highlight/detail?id=2674833650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674833650?lang=en_us&edition=fundamental","pubTime":"2026-10-09 13:25","pubTimestamp":1791523553,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nFWN45V0E3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IE00B2B36J28.USD","LU0889565916.HKD","BK4588","LU0109394709.USD","BK4585","ARGX","IBB","LU0390134368.USD","LU0823416689.USD","TBXU","FMED","IE0009355771.USD","IE0002141913.USD","BK4505","LU0320765992.SGD","IE00BJT1NW94.SGD","IE0034235188.USD","LU2324357040.USD","IE00BJJMRZ35.SGD","LU1983260115.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674283866","title":"C4 Therapeutics, Inc. : JP Morgan Initiates Coverage with Overweight Rating; Price Target $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2674283866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674283866?lang=en_us&edition=fundamental","pubTime":"2026-10-09 12:41","pubTimestamp":1791520900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nFWN45V01W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CCCC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674800768","title":"Alterity Therapeutics to Present at Canaccord Genuity Drug and Device Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2674800768","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674800768?lang=en_us&edition=fundamental","pubTime":"2026-10-09 12:07","pubTimestamp":1791518857,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics ( ($AU:ATH) ) has issued an announcement. Alterity Therapeutics will participate in the Canaccord Genuity Drug and Device Con...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-to-present-at-canaccord-genuity-drug-and-device-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-to-present-at-canaccord-genuity-drug-and-device-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674887574","title":"Legend Biotech Corporation : JP Morgan Cuts Target Price to $33 from $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2674887574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674887574?lang=en_us&edition=fundamental","pubTime":"2026-10-09 11:10","pubTimestamp":1791515420,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nFWN45U23Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","MEDI","LEGN","BK4588","MEMS","CANC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674088087","title":"Nurix Therapeutics (NRIX) Starts New CLL Trial, Is The 11% Discount Warranted?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674088087","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674088087?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:37","pubTimestamp":1791513449,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics (NRIX) has enrolled the first patient in its Phase 1b/2 NX-5948-203 trial, which pairs its BTK degrader bexobrutideg with venetoclax for chronic lymphocytic leukemia as part of a broader collaboration with Roche.\nNurix Therapeutics’ recent headlines around its Roche and Gilead collaborations come against a mixed trading backdrop, with the share price down 15.0% over the past month but still showing a 22.98% year to date share price return and a 104.51% total shareholder...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-starts-new-cll-trial-is-the-11-disco","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-starts-new-cll-trial-is-the-11-disco","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674383198","title":"Is Rare Disease Approval Altering The Investment Case For Incyte (INCY)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674383198","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674383198?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:36","pubTimestamp":1791513417,"startTime":"0","endTime":"0","summary":"Incyte and Mirum Pharmaceuticals reported that the U.S. FDA previously approved Atebrioz (zilurgisertib), an oral ALK2 inhibitor for Fibrodysplasia Ossificans Progressiva in patients aged 12 and older, and granted Incyte a Rare Pediatric Disease Priority Review Voucher.\nThe approval of Atebrioz adds a rare disease product and a transferable FDA voucher to Incyte’s toolkit. This development could influence how the business funds and prioritizes its planned shift toward a broader,...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/is-rare-disease-approval-altering-the-investment-case-for-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/is-rare-disease-approval-altering-the-investment-case-for-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","INCY","BK4585","IDNA","BK4532","BK4139","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674488039","title":"Amgen (AMGN) In Focus As MariTide Buzz Tests Whether The Stock Is Fully Valued","url":"https://stock-news.laohu8.com/highlight/detail?id=2674488039","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674488039?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:36","pubTimestamp":1791513400,"startTime":"0","endTime":"0","summary":"Amgen (AMGN) is back in focus after fresh attention on its obesity drug candidate MariTide, now in late-stage Phase III testing, and new precision medicine partnerships that together are shaping sentiment toward the stock.\nThose headlines are landing on a stock that has already been rebuilding confidence. Amgen’s share price is up 12.12% over 90 days and 24.36% year to date, while its 1-year total shareholder return of 41.74% points to strong, dividend-backed momentum rather than a...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/24816-card/1789038959684","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/24816-card/1789038959684"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-in-focus-as-maritide-buzz-tests-whether-the-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-in-focus-as-maritide-buzz-tests-whether-the-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0889565916.HKD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IBB","BK4588","LU0868494617.USD","LU0058720904.USD","LU2112291526.USD","AMGN","LU2089984988.USD","LU2242646821.SGD","LU0320765992.SGD","LU2242652126.USD","BK4533","PJP","IE0009355771.USD","SG9999001440.SGD","LU1983299246.USD","BK4534","BBH","LU0289739699.SGD","LU1023059063.AUD","LU0109394709.USD","LU0122379950.USD","BK4139","LU1571399168.USD","BIB","IBBQ","TBXU","BK4566","IE00B2B36J28.USD","LU2468319806.SGD","BK4599","LU1057294990.SGD","PBE","IE00B4R5TH58.HKD","LU1061106388.HKD","IE0002141913.USD","BK4581","IE00BJT1NW94.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674386880","title":"Celcuity (CELC) Launches REVTORPYK On A Narrative That Says It May Still Be Undervalued","url":"https://stock-news.laohu8.com/highlight/detail?id=2674386880","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674386880?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:34","pubTimestamp":1791513257,"startTime":"0","endTime":"0","summary":"The latest move at Celcuity (CELC) is not about trial data or sales figures. The firm recently added David W. Gryska to its board and key committees.\nCelcuity’s share price has been under pressure recently, with the stock down 27.04% over the past 30 days and 36.91% over 90 days. However, the 1-year total shareholder return of 37.19% and the more than 7x 3-year total shareholder return point to longer term momentum. This contrasts with the current pullback and reflects shifting views on both...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/celcuity-celc-launches-revtorpyk-on-a-narrative-that-says-it","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/celcuity-celc-launches-revtorpyk-on-a-narrative-that-says-it","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674412882","title":"Truist Financial Remains a Buy on BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674412882","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674412882?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:25","pubTimestamp":1791512718,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Gregory Renza from Truist Financial maintained a Buy rating on BeOne Medicines, with a price target of $420.00. Acc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-remains-a-buy-on-beone-medicines-onc-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-remains-a-buy-on-beone-medicines-onc-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","MDCO","ONC","BK4585","BK4139","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674882478","title":"Genmab (GMAB) Receives a Buy from Truist Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2674882478","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674882478?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:25","pubTimestamp":1791512714,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Gregory Renza maintained a Buy rating on Genmab yesterday and set a price target of $45.00. According to TipRanks, Renza i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/genmab-gmab-receives-a-buy-from-truist-financial-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/genmab-gmab-receives-a-buy-from-truist-financial-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GMAB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674049884","title":"Everest Medicines Appoints Ex-Moderna Executive Lakshmi Srinivasan as Head of Translational Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2674049884","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674049884?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:13","pubTimestamp":1791512025,"startTime":"0","endTime":"0","summary":"Everest Medicines appoints ex-Moderna executive Lakshmi Srinivasan as head of translational medicineEverest Medicines appointed Lakshmi Srinivasan as senior vice president, head of translational medic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nNDL9xdVL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","GNOM","MRNX","BK4568","BK4551","BK1161","MRNY","BK4534","WDNA","BK1574","BK4548","BK4532","BK4501","01952","BK1583","LGHT","MRNA","BK4585","IDNA","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674823408","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2674823408","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674823408?lang=en_us&edition=fundamental","pubTime":"2026-10-09 09:50","pubTimestamp":1791510620,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CSL (CMXHF), Ionis Pharmaceuticals (IONS) and Cormed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-375?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-375?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","IONS","LU0128526141.USD","XLV","BK4139","CMXHF","BK4585","BK4588","BK4137","HCSG","LU0029874061.USD","XBI","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674882317","title":"RBC Capital Remains a Hold on Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674882317","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674882317?lang=en_us&edition=fundamental","pubTime":"2026-10-09 09:47","pubTimestamp":1791510478,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Luca Issi maintained a Hold rating on Moderna yesterday and set a price target of $130.00. According to TipRanks, Issi is an an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-hold-on-moderna-mrna-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-hold-on-moderna-mrna-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4551","LU0128525929.USD","GNOM","BK4139","BK4207","BK4568","IDNA","LU0708994859.HKD","LU1267930573.SGD","LU0029864427.USD","LU0310800379.SGD","BK4534","BK4588","GSIB","MRNA","BK4585","BK4533","LGHT","WDNA","BK4532","BK4501","MRNX","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674888234","title":"Agios Pharma (AGIO) Gets a Hold from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2674888234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674888234?lang=en_us&edition=fundamental","pubTime":"2026-10-09 09:47","pubTimestamp":1791510452,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Luca Issi maintained a Hold rating on Agios Pharma yesterday and set a price target of $32.00. According to TipRanks, Issi is a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/agios-pharma-agio-gets-a-hold-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/agios-pharma-agio-gets-a-hold-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029864427.USD","LU0708994859.HKD","AGIO","BK4139","BK4207","LU1267930573.SGD","GSIB","LU0128525929.USD","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674392882","title":"Argenx Se (ARGX) Receives a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2674392882","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674392882?lang=en_us&edition=fundamental","pubTime":"2026-10-09 09:47","pubTimestamp":1791510436,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Argenx Se, with a price target of $1,100.00. According to Tip...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/argenx-se-argx-receives-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/argenx-se-argx-receives-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0034235188.USD","LU0390134368.USD","ARGX","GSIB","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4585","LU1267930573.SGD","IE00BJT1NW94.SGD","BK4505","LU2324357040.USD","LU0128525929.USD","LU0029864427.USD","IE00B4R5TH58.HKD","FMED","LU0708994859.HKD","LU0889565916.HKD","TBXU","LU0320765992.SGD","LU1983260115.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","IBB","LU0109394709.USD","IE0009355771.USD","LU0823416689.USD","BK4139","BK4207","LU0310800379.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674880809","title":"Denali Therapeutics (DNLI) Dropped, So What Is Drawing Attention Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674880809","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674880809?lang=en_us&edition=fundamental","pubTime":"2026-10-09 09:34","pubTimestamp":1791509651,"startTime":"0","endTime":"0","summary":"Denali Therapeutics (DNLI) drew investor attention after its shares closed at $18.67, giving the biopharma business a market value near $3.1 billion and reflecting a history of mixed long-term returns.\nRecent trading has been choppy for Denali Therapeutics, with the share price down 2.56% on the day and falling 27.30% over the past 90 days, yet still showing a 14.75% year to date share price return and a 15.46% total shareholder return over one year. This indicates that longer term holders...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/denali-therapeutics-dnli-dropped-so-what-is-drawing-attentio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/denali-therapeutics-dnli-dropped-so-what-is-drawing-attentio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4548","DNLI","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674886636","title":"Halozyme CEO Helen Torley Disposes of 48,000 Common Shares Worth $5.31 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2674886636","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674886636?lang=en_us&edition=fundamental","pubTime":"2026-10-09 07:57","pubTimestamp":1791503822,"startTime":"0","endTime":"0","summary":"Halozyme CEO Helen Torley disposes of 48,000 common shares worth $5.31 millionHalozyme filed a Form 4 showing President and CEO Helen Torley exercised options for 60,000 shares at $18.41 on Oct. 6-8.S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL10h7dY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Halozyme CEO Helen Torley Disposes of 48,000 Common Shares Worth $5.31 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HALO","LU0053671581.USD","FFOX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":0.0104},{"period":"3month","weight":0.0251},{"period":"6month","weight":0.139},{"period":"1year","weight":0.1498},{"period":"ytd","weight":0.1349}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}